市場調查報告書

全球硬皮症治療藥市場:產業趨勢與預測

Global Scleroderma Therapeutics Market - Industry Trends and Forecast to 2026

出版商 Data Bridge Market Research Private Limited 商品編碼 836099
出版日期 內容資訊 英文 217 Pages
商品交期: 最快1-2個工作天內
價格
全球硬皮症治療藥市場:產業趨勢與預測 Global Scleroderma Therapeutics Market - Industry Trends and Forecast to 2026
出版日期: 2019年04月01日內容資訊: 英文 217 Pages
簡介

本報告提供全球硬皮症治療藥市場相關調查,彙整市場趨勢與各市場區隔趨勢,各地區預測,加入此市場的主要企業的簡介相關資訊。

第1章 簡介

第2章 市場區隔

第3章 市場概要

  • 促進要素
  • 阻礙要素
  • 機會
  • 課題

第4章 摘要整理

第5章 高級見解

第6章 開發中產品

第7章 流行病學

  • 硬皮症的歷史
  • 近幾年的發病率和罹患率
  • 硬皮症的原因
  • 硬皮症的症狀
  • 硬皮症的管理

第8章 各類型市場

  • 概要
  • 全身性硬皮症
  • 局部性硬皮症

第9章 各治療類型市場

  • 概要
  • 藥物治療
  • 外科治療
  • 療法

第10章 各終端用戶市場

  • 概要
  • 醫院
  • 專門診所
  • 居家照護
  • 其他

第11章 各地區市場

  • 概要
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東·非洲

第12章 企業趨勢

第13章 企業簡介

第14章 問題事項

第15章 相關報告

目錄

Global scleroderma therapeutics market is expected to grow at a CAGR of 5.2% in the forecast period of 2019 to 2026. The new market report contains data for historic year 2017, the base year of calculation is 2018 and the forecast period is 2019 to 2026.

Market Segmentation:

By Type (Localized Scleroderma, Systemic Scleroderma), Treatment Type (Drug Treatment, Surgical Treatment, Therapy), End User (Hospital, Specialty Clinics, Homecare Settings, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) Industry Trends and Forecast to 2026

Major growing sectors under the market segmentation are as follows:

  • In type, systemic scleroderma segment is dominating due to its awareness and treatment availability for its associated diseases. There are many products for this segment on which the clinical trials are going on.
  • In treatment type, the drug treatment is growing segment as there are various drugs available in the market for the treatment of scleroderma related complications.
  • In end user, hospital has a larger market than other end users because the treatment takes place majorly in hospitals.

Key Market Players:

The key market players for global scleroderma therapeutics market are listed below:

  • Argentis Pharmaceuticals, LLC.
  • F. Hoffmann-La Roche Ltd
  • AbbVie Inc.
  • Pfizer Inc.
  • Sanofi
  • ALLERGAN
  • viDA Therapeutics Inc.
  • Novartis AG
  • Active Biotech AB.
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline plc.
  • Johnson & Johnson Services, Inc.
  • AstraZeneca
  • Daval International Limited
  • Others

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 OVERVIEW OF GLOBAL SCLERODERMA THERAPEUTICS MARKET
  • 1.4 CURRENCY AND PRICING
  • 1.5 LIMITATIONS
  • 1.6 MARKETS COVERED

2 MARKET SEGMENTATION

  • 2.1 MARKETS COVERED
  • 2.2 GLOBAL SCLERODERMA THERAPEUTICS MARKET : GEOGRAPHICAL SCOPE
  • 2.3 YEARS CONSIDERED FOR THE STUDY
  • 2.4 CURRENCY AND PRICING
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL
  • 2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
  • 2.7 DBMR MARKET POSITION GRID
  • 2.8 TIME LINE
  • 2.9 MULTIVARIATE MODELLING
  • 2.10 SECONDARY SOURCES
  • 2.11 ASSUMPTIONS

3 MARKET OVERVIEW

  • 3.1 DRIVERS
    • 3.1.1 RISING CASES OF SCLERODERMA
    • 3.1.2 INCREASING ACCESS TO MEDICAL INSURANCE IN THE U.S.
    • 3.1.3 INCREASING MERGER AND ACQUISITIONS
  • 3.2 RESTRAINTS
    • 3.2.1 LACK OF CURATIVE TREATMENT
    • 3.2.2 STRINGENT REGULATIONS
    • 3.2.3 COUNTERFEIT PRODUCTS
  • 3.3 OPPORTUNITY
    • 3.3.1 UNMET PATIENT NEEDS IN SYSTEMIC SCLEROSIS
  • 3.4 CHALLENGE
    • 3.4.1 SIDE EFFECTS OF DRUGS

4 EXECUTIVE SUMMARY

5 PREMIUM INSIGHTS

6 PIPELINE PRODUCTS

7 EPIDEMIOLOGY

  • 7.1 HISTORY OF SCLERODERMA:
  • 7.2 RECENT INCIDENCE AND PREVALENCE:
  • 7.3 CAUSE OF SCLERODERMA:
  • 7.4 SYMPTOMS OF SCLERODERMA:
  • 7.5 MANAGING SCLERODERMA:

8 GLOBAL SCLERODERMA THERAPEUTICS MARKET, BY TYPE

  • 8.1 OVERVIEW
  • 8.2 SYSTEMIC SCLERODERMA
    • 8.2.1 LIMITED CUTANEOUS SYSTEMIC SCLEROSIS OR CREST SYNDROME
    • 8.2.2 DIFFUSE SYSTEMIC SCLEROSIS
  • 8.3 LOCALIZED SCLERODERMA
    • 8.3.1 MORPHEA
    • 8.3.2 LINEAR SCLERODERMA

9 GLOBAL SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE

  • 9.1 OVERVIEW
  • 9.2 DRUG TREATMENT
    • 9.2.1 DRUG TREATMENT, BY TYPE
      • 9.2.1.1 ANTI-INFLAMMATORY DRUGS
      • 9.2.1.2 IMMUNOSUPPRESSANTS
      • 9.2.1.3 CORTICOSTEROIDS
      • 9.2.1.4 PROTON PUMP INHIBITORS
      • 9.2.1.5 CALCIUM CHANNEL BLOCKERS
      • 9.2.1.6 ACE INHIBITORS
      • 9.2.1.7 H2 BLOCKERS
      • 9.2.1.8 PDE5 INHIBITORS
      • 9.2.1.9 PROSTACYCLIN ANALOGUES
      • 9.2.1.10 ENDOTHELIN RECEPTOR ANTAGONISTS
      • 9.2.1.11 CHELATING AGENTS (EDATHAMIL DISODIUM)
      • 9.2.1.12 OTHERS
    • 9.2.2 DRUG TREATMENT, BY DISTRIBUTION CHANNEL
      • 9.2.2.1 HOSPITAL PHARMACY
      • 9.2.2.2 RETAIL PHARMACY
      • 9.2.2.3 ONLINE PHARMACY
      • 9.2.2.4 OTHERS
  • 9.3 SURGICAL TREATMENT
  • 9.4 THERAPY
    • 9.4.1 ULTRAVIOLET LIGHT THERAPY
    • 9.4.2 PHYSICAL THERAPY
    • 9.4.3 OTHERS

10 GLOBAL SCLERODERMA THERAPEUTICS MARKET, BY END USER

  • 10.1 OVERVIEW
  • 10.2 HOSPITAL
  • 10.3 SPECIALTY CLINICS
  • 10.4 HOMECARE SETTINGS
  • 10.5 OTHERS

11 GLOBAL SCLERODERMA THERAPEUTICS MARKET, BY GEOGRAPHY

  • 11.1 OVERVIEW
  • 11.2 NORTH AMERICA
    • 11.2.1 U.S.
    • 11.2.2 CANADA
    • 11.2.3 MEXICO
  • 11.3 EUROPE
    • 11.3.1 U.K.
    • 11.3.2 GERMANY
    • 11.3.3 FRANCE
    • 11.3.4 SPAIN
    • 11.3.5 ITALY
    • 11.3.6 NETHERLANDS
    • 11.3.7 SWITZERLAND
    • 11.3.8 BELGIUM
    • 11.3.9 TURKEY
    • 11.3.10 RUSSIA
    • 11.3.11 REST OF EUROPE
  • 11.4 ASIA-PACIFIC
    • 11.4.1 JAPAN
    • 11.4.2 CHINA
    • 11.4.3 AUSTRALIA
    • 11.4.4 SOUTH KOREA
    • 11.4.5 INDIA
    • 11.4.6 SINGAPORE
    • 11.4.7 MALAYSIA
    • 11.4.8 INDONESIA
    • 11.4.9 THAILAND
    • 11.4.10 PHILIPPINES
    • 11.4.11 REST OF ASIA-PACIFIC
  • 11.5 SOUTH AMERICA
    • 11.5.1 BRAZIL
    • 11.5.2 REST OF SOUTH AMERICA
  • 11.6 MIDDLE EAST & AFRICA
    • 11.6.1 SOUTH AFRICA
    • 11.6.2 REST OF MIDDLE EAST & AFRICA

12 GLOBAL SCLERODERMA THERAPEUTICS MARKET, COMPANY LANDSCAPE

  • 12.1 COMPANY SHARE ANALYSIS: GLOBAL

13 COMPANY PROFILES

  • 13.1 ASTRAZENECA
    • 13.1.1 COMPANY SNAPSHOT
    • 13.1.2 REVENUE ANALYSIS
    • 13.1.3 GEOGRAPHICAL PRESENCE
    • 13.1.4 PRODUCT PORTFOLIO (PIPELINE)
    • 13.1.5 RECENT DEVELOPMENTS
  • 13.2 F. HOFFMANN-LA ROCHE LTD
    • 13.2.1 COMPANY SNAPSHOT
    • 13.2.2 REVENEUE ANALYSIS
    • 13.2.3 GEOGRAPHICAL PRESENCE
    • 13.2.4 PRODUCT PORTFOLIO
    • 13.2.5 RECENT DEVELOPMENTS
  • 13.3 NOVARTIS AG
    • 13.3.1 COMPANY SNAPSHOT
    • 13.3.2 REVENEUE ANALYSIS
    • 13.3.3 GEOGRAPHICAL PRESENCE
    • 13.3.4 PRODUCT PORTFOLIO
    • 13.3.5 RECENT DEVELOPMENTS
  • 13.4 PFIZER INC.
    • 13.4.1 COMPANY SNAPSHOT
    • 13.4.2 REVENEUE ANALYSIS
    • 13.4.3 GEOGRAPHICAL PRESENCE
    • 13.4.4 PRODUCT PORTFOLIO
    • 13.4.5 RECENT DEVELOPMENTS
  • 13.5 ABBVIE INC.
    • 13.5.1 COMPANY SNAPSHOT
    • 13.5.2 REVENEUE ANALYSIS
    • 13.5.3 GEOGRAPHICAL PRESENCE
    • 13.5.4 PRODUCT PORTFOLIO
    • 13.5.5 RECENT DEVELOPMENTS
  • 13.6 ACTIVE BIOTECH AB.
    • 13.6.1 COMPANY OVERVIEW
    • 13.6.2 REVENUE ANALYSIS
    • 13.6.3 PRODUCT PORTFOLIO
    • 13.6.4 RECENT DEVELOPMENT
  • 13.7 ALLERGAN
    • 13.7.1 COMPANY SNAPSHOT
    • 13.7.2 REVENEUE ANALYSIS
    • 13.7.3 GEOGRAPHICAL PRESENCE
    • 13.7.4 PRODUCT PORTFOLIO
    • 13.7.5 RECENT DEVELOPMENTS
  • 13.8 ARGENTIS PHARMACEUTICALS, LLC.
    • 13.8.1 COMPANY OVERVIEW
    • 13.8.2 PRODUCT PORTFOLIO
    • 13.8.3 RECENT DEVELOPMENTS
  • 13.9 BRISTOL-MYERS SQUIBB COMPANY
    • 13.9.1 COMPANY OVERVIEW
    • 13.9.2 REVENUE ANALYSIS
    • 13.9.3 GEOGRAPHICAL PRESENCE
    • 13.9.4 PRODUCTS PORTFOLIO
    • 13.9.5 RECENT DEVELOPMENTS
  • 13.10 DAVAL INTERNATIONAL LIMITED
    • 13.10.1 COMPANY SNAPSHOT
    • 13.10.2 GEOGRAPHICAL PRESENCE
    • 13.10.3 PRODUCT PORTFOLIO
    • 13.10.4 RECENT DEVELOPMENT
  • 13.11 GLAXOSMITHKLINE PLC.
    • 13.11.1 COMPANY OVERVIEW
    • 13.11.2 REVENUE ANALYSIS
    • 13.11.3 GEOGRAPHICAL PRESENCE
    • 13.11.4 PRODUCTS PORTFOLIO (PIPELINE DEVELOPMENT)
    • 13.11.5 RECENT DEVELOPMENT
  • 13.12 JOHNSON & JOHNSON SERVICES, INC.
    • 13.12.1 COMPANY OVERVIEW
    • 13.12.2 REVENUE ANALYSIS
    • 13.12.3 GEOGRAPHICAL PRESENCE
    • 13.12.4 PRODUCT PORTFOLIO (PIPELINE)
    • 13.12.5 RECENT DEVELOPMENTS
  • 13.13 SANOFI
    • 13.13.1 COMPANY SNAPSHOT
    • 13.13.2 REVENEUE ANALYSIS
    • 13.13.3 GEOGRAPHICAL PRESENCE
    • 13.13.4 PRODUCT PORTFOLIO
    • 13.13.5 RECENT DEVELOPMENT
  • 13.14 VIDA THERAPEUTICS INC.
    • 13.14.1 COMPANY OVERVIEW
    • 13.14.2 PRODUCT PORTFOLIO
    • 13.14.3 RECENT DEVELOPMENTS

14 QUESTIONNAIRE

15 RELATED REPORTS

LIST OF TABLES

  • TABLE 1: INSIGHTS ABOUT CLINICAL TRIAL PHASES OF VARIOUS DRUGS
  • TABLE 2: INCIDENCE AND PREVALENCE IN PAST DECADE (REGION)
  • TABLE 3: GLOBAL SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 4: GLOBAL SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY REGION 2017-2026 (USD MILLION)
  • TABLE 5: GLOBAL SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 6: GLOBAL LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY REGION 2017-2026 (USD MILLION)
  • TABLE 7: GLOBAL LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 8: GLOBAL SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 9: GLOBAL DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 10: GLOBAL DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 11: GLOBAL DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 12: GLOBAL SURGICAL TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY REGION 2017-2026 (USD MILLION)
  • TABLE 13: GLOBAL THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 14: GLOBAL THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 15: GLOBAL SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 16: GLOBAL HOSPITAL IN SCLERODERMA THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 17: GLOBAL SPECIALTY CLINICS IN SCLERODERMA THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 18: GLOBAL HOMECARE SETTINGS IN SCLERODERMA THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 19: GLOBAL OTHERS IN SCLERODERMA THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 20: GLOBAL SCLERODERMA THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 21: NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET, BY COUNTRY, 2017-2026 (USD MILLION)
  • TABLE 22: NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 23: NORTH AMERICA LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 24: NORTH AMERICA SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 25: NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 26: NORTH AMERICA DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 27: NORTH AMERICA DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 28: NORTH AMERICA THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 29: NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 30: U.S. SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 31: U.S. LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 32: U.S. SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 33: U.S. SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 34: U.S. DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 35: U.S. DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 36: U.S. THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 37: U.S. SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 38: CANADA SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 39: CANADA LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 40: CANADA SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 41: CANADA SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 42: CANADA DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 43: CANADA DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 44: CANADA THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 45: CANADA SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 46: MEXICO SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 47: MEXICO LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 48: MEXICO SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 49: MEXICO SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 50: MEXICO DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 51: MEXICO DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 52: MEXICO THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 53: MEXICO SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 54: EUROPE SCLERODERMA THERAPEUTICS MARKET, BY COUNTRY, 2017-2026 (USD MILLION)
  • TABLE 55: EUROPE SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 56: EUROPE LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 57: EUROPE SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 58: EUROPE SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 59: EUROPE DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 60: EUROPE DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 61: EUROPE THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 62: EUROPE SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 63: U.K. SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 64: U.K. LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 65: U.K. SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 66: U.K. SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 67: U.K. DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 68: U.K. DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 69: U.K. THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 70: U.K. SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 71: GERMANY SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 72: GERMANY LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 73: GERMANY SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 74: GERMANY SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 75: GERMANY DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 76: GERMANY DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 77: GERMANY THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 78: GERMANY SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 79: FRANCE SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 80: FRANCE LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 81: FRANCE SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 82: FRANCE SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 83: FRANCE DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 84: FRANCE DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 85: FRANCE THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 86: FRANCE SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 87: SPAIN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 88: SPAIN LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 89: SPAIN SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 90: SPAIN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 91: SPAIN DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 92: SPAIN DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 93: SPAIN THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 94: SPAIN SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 95: ITALY SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 96: ITALY LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 97: ITALY SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 98: ITALY SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 99: ITALY DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 100: ITALY DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 101: ITALY THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 102: ITALY SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 103: NETHERLANDS SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 104: NETHERLANDS LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 105: NETHERLANDS SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 106: NETHERLANDS SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 107: NETHERLANDS DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 108: NETHERLANDS DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 109: NETHERLANDS THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 110: NETHERLANDS SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 111: SWITZERLAND SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 112: SWITZERLAND LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 113: SWITZERLAND SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 114: SWITZERLAND SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 115: SWITZERLAND DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 116: SWITZERLAND DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 117: SWITZERLAND THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 118: SWITZERLAND SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 119: BELGIUM SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 120: BELGIUM LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 121: BELGIUM SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 122: BELGIUM SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 123: BELGIUM DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 124: BELGIUM DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 125: BELGIUM THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 126: BELGIUM SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 127: TURKEY SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 128: TURKEY LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 129: TURKEY SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 130: TURKEY SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 131: TURKEY DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 132: TURKEY DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 133: TURKEY THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 134: TURKEY SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 135: RUSSIA SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 136: RUSSIA LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 137: RUSSIA SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 138: RUSSIA SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 139: RUSSIA DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 140: RUSSIA DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 141: RUSSIA THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 142: RUSSIA SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 143: REST OF EUROPE SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 144: ASIA-PACIFIC SCLERODERMA THERAPEUTICS MARKET, BY COUNTRY, 2017-2026 (USD MILLION)
  • TABLE 145: ASIA-PACIFIC SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 146: ASIA-PACIFIC LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 147: ASIA-PACIFIC SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 148: ASIA-PACIFIC SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 149: ASIA-PACIFIC DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 150: ASIA-PACIFIC DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 151: ASIA-PACIFIC THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 152: ASIA-PACIFIC SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 153: JAPAN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 154: JAPAN LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 155: JAPAN SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 156: JAPAN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 157: JAPAN DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 158: JAPAN DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 159: JAPAN THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 160: JAPAN SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 161: CHINA SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 162: CHINA LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 163: CHINA SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 164: CHINA SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 165: CHINA DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 166: CHINA DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 167: CHINA THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 168: CHINA SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 169: AUSTRALIA SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 170: AUSTRALIA LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 171: AUSTRALIA SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 172: AUSTRALIA SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 173: AUSTRALIA DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 174: AUSTRALIA DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 175: AUSTRALIA THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 176: AUSTRALIA SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 177: SOUTH KOREA SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 178: SOUTH KOREA LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 179: SOUTH KOREA SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 180: SOUTH KOREA SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 181: SOUTH KOREA DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 182: SOUTH KOREA DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 183: SOUTH KOREA THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 184: SOUTH KOREA SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 185: INDIA SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 186: INDIA LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 187: INDIA SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 188: INDIA SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 189: INDIA DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 190: INDIA DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 191: INDIA THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 192: INDIA SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 193: SINGAPORE SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 194: SINGAPORE LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 195: SINGAPORE SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 196: SINGAPORE SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 197: SINGAPORE DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 198: SINGAPORE DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 199: SINGAPORE THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 200: SINGAPORE SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 201: MALAYSIA SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 202: MALAYSIA LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 203: MALAYSIA SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 204: MALAYSIA SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 205: MALAYSIA DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 206: MALAYSIA DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 207: MALAYSIA THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 208: MALAYSIA SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 209: INDONESIA SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 210: INDONESIA LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 211: INDONESIA SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 212: INDONESIA SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 213: INDONESIA DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 214: INDONESIA DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 215: INDONESIA THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 216: INDONESIA SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 217: THAILAND SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 218: THAILAND LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 219: THAILAND SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 220: THAILAND SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 221: THAILAND DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 222: THAILAND DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 223: THAILAND THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 224: THAILAND SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 225: PHILIPPINES SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 226: PHILIPPINES LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 227: PHILIPPINES SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 228: PHILIPPINES SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 229: PHILIPPINES DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 230: PHILIPPINES DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 231: PHILIPPINES THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 232: PHILIPPINES SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 233: REST OF ASIA-PACIFIC SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 234: SOUTH AMERICA SCLERODERMA THERAPEUTICS MARKET, BY COUNTRY, 2017-2026 (USD MILLION)
  • TABLE 235: SOUTH AMERICA SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 236: SOUTH AMERICA LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 237: SOUTH AMERICA SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 238: SOUTH AMERICA SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 239: SOUTH AMERICA DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 240: SOUTH AMERICA DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 241: SOUTH AMERICA THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 242: SOUTH AMERICA SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 243: BRAZIL SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 244: BRAZIL LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 245: BRAZIL SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 246: BRAZIL SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 247: BRAZIL DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 248: BRAZIL DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 249: BRAZIL THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 250: BRAZIL SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 251: REST OF SOUTH AMERICA SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 252: MIDDLE EAST & AFRICA SCLERODERMA THERAPEUTICS MARKET, BY COUNTRY, 2017-2026 (USD MILLION)
  • TABLE 253: MIDDLE EAST & AFRICA SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 254: MIDDLE EAST & AFRICA LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 255: MIDDLE EAST & AFRICA SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 256: MIDDLE EAST & AFRICA SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 257: MIDDLE EAST & AFRICA DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 258: MIDDLE EAST & AFRICA DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 259: MIDDLE EAST & AFRICA THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 260: MIDDLE EAST & AFRICA SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 261: SOUTH AFRICA SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 262: SOUTH AFRICA LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 263: SOUTH AFRICA SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 264: SOUTH AFRICA SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 265: SOUTH AFRICA DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 266: SOUTH AFRICA DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 267: SOUTH AFRICA THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION)
  • TABLE 268: SOUTH AFRICA SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 269: REST OF MIDDLE EAST & AFRICA SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)

LIST OF FIGURES

  • FIGURE 1 BELOW IS THE SCLERODERMA MAP DEFINING THE TYPES
  • FIGURE 2 GLOBAL SCLERODERMA THERAPEUTICS MARKET: SEGMENTATION
  • FIGURE 3 GLOBAL SCLERODERMA THERAPEUTICS MARKET: DATA TRIANGULATION
  • FIGURE 4 GLOBAL SCLERODERMA THERAPEUTICS MARKET: DROC ANALYSIS
  • FIGURE 5 GLOBAL SCLERODERMA THERAPEUTICS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
  • FIGURE 6 GLOBAL SCLERODERMA THERAPEUTICS MARKET: COMPANY RESEARCH ANALYSIS
  • FIGURE 7 GLOBAL SCLERODERMA THERAPEUTICS MARKET: INTERVIEW DEMOGRAPHICS
  • FIGURE 8 GLOBAL SCLERODERMA THERAPEUTICS MARKET: DBMR MARKET POSITION GRID
  • FIGURE 9 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF GLOBAL SCLERODERMA THERAPEUTICS MARKET
  • FIGURE 10 GLOBAL SCLERODERMA THERAPEUTICS MARKET: SEGMENTATION
  • FIGURE 11 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE GLOBAL SCLERODERMA THERAPEUTICS MARKET AND ESTIMATED TO BE INCREASING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD FROM 2019 TO 2026
  • FIGURE 12 RISING CASES OF SCLERODERMA, INCREASING ACCESS TO MEDICAL INSURANCE IN THE U.S., INCREASING MERGER AND ACQUISITIONS IS EXPECTED TO DRIVE THE GLOBAL SCLERODERMA THERAPEUTICS MARKET IN THE FORECAST PERIOD 2019 TO 2026
  • FIGURE 13 SYSTEMIC SCLERODERMA IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL SCLERODERMA THERAPEUTICS MARKET IN 2019 & 2026
  • FIGURE 14 NORTH AMERICA IS THE MAXIMUM GROWING AND MOST PROFITABLE REVENUE POCKETS FOR GLOBAL SCLERODERMA THERAPEUTICS MARKET IN THE FORECAST PERIOD FROM 2019 TO 2026
  • FIGURE 15 GLOBAL SCLERODERMA THERAPEUTICS MARKET: BY TYPE , 2018
  • FIGURE 16 GLOBAL SCLERODERMA THERAPEUTICS MARKET: BY TREATMENT TYPE , 2018
  • FIGURE 17 GLOBAL SCLERODERMA THERAPEUTICS MARKET: BY END USER, 2018
  • FIGURE 18 GLOBAL SCLERODERMA THERAPEUTICS MARKET: SNAPSHOT (2018)
  • FIGURE 19 GLOBAL SCLERODERMA THERAPEUTICS MARKET: BY GEOGRAPHY (2018)
  • FIGURE 20 GLOBAL SCLERODERMA THERAPEUTICS MARKET: BY GEOGRAPHY (2019 & 2026)
  • FIGURE 21 GLOBAL SCLERODERMA THERAPEUTICS MARKET: BY GEOGRAPHY (2018 & 2026)
  • FIGURE 22 GLOBAL SCLERODERMA THERAPEUTICS MARKET: BY TYPE (2019-2026)
  • FIGURE 23 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET: SNAPSHOT (2018)
  • FIGURE 24 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET: BY COUNTRY (2018)
  • FIGURE 25 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET: BY COUNTRY (2019 & 2026)
  • FIGURE 26 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET: BY COUNTRY (2018 & 2026)
  • FIGURE 27 NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET: BY TYPE (2019-2026)
  • FIGURE 28 EUROPE SCLERODERMA THERAPEUTICS MARKET: SNAPSHOT (2018)
  • FIGURE 29 EUROPE SCLERODERMA THERAPEUTICS MARKET: BY COUNTRY (2018)
  • FIGURE 30 EUROPE SCLERODERMA THERAPEUTICS MARKET: BY COUNTRY (2019 & 2026)
  • FIGURE 31 EUROPE SCLERODERMA THERAPEUTICS MARKET: BY COUNTRY (2018 & 2026)
  • FIGURE 32 EUROPE SCLERODERMA THERAPEUTICS MARKET: BY TYPE (2019-2026)
  • FIGURE 33 ASIA-PACIFIC SCLERODERMA THERAPEUTICS MARKET: SNAPSHOT (2018)
  • FIGURE 34 ASIA-PACIFIC SCLERODERMA THERAPEUTICS MARKET: BY COUNTRY (2018)
  • FIGURE 35 ASIA-PACIFIC SCLERODERMA THERAPEUTICS MARKET: BY COUNTRY (2019 & 2026)
  • FIGURE 36 ASIA-PACIFIC SCLERODERMA THERAPEUTICS MARKET: BY COUNTRY (2018 & 2026)
  • FIGURE 37 ASIA-PACIFIC SCLERODERMA THERAPEUTICS MARKET: BY TYPE (2019-2026)
  • FIGURE 38 SOUTH AMERICA SCLERODERMA THERAPEUTICS MARKET: SNAPSHOT (2018)
  • FIGURE 39 SOUTH AMERICA SCLERODERMA THERAPEUTICS MARKET: BY COUNTRY (2018)
  • FIGURE 40 SOUTH AMERICA SCLERODERMA THERAPEUTICS MARKET: BY COUNTRY (2019 & 2026)
  • FIGURE 41 SOUTH AMERICA SCLERODERMA THERAPEUTICS MARKET: BY COUNTRY (2018 & 2026)
  • FIGURE 42 SOUTH AMERICA SCLERODERMA THERAPEUTICS MARKET: BY TYPE (2019-2026)
  • FIGURE 43 MIDDLE EAST & AFRICA SCLERODERMA THERAPEUTICS MARKET: SNAPSHOT (2018)
  • FIGURE 44 MIDDLE EAST & AFRICA SCLERODERMA THERAPEUTICS MARKET: BY COUNTRY (2018)
  • FIGURE 45 MIDDLE EAST & AFRICA SCLERODERMA THERAPEUTICS MARKET: BY COUNTRY (2019 & 2026)
  • FIGURE 46 MIDDLE EAST & AFRICA SCLERODERMA THERAPEUTICS MARKET: BY COUNTRY (2018 & 2026)
  • FIGURE 47 MIDDLE EAST & AFRICA SCLERODERMA THERAPEUTICS MARKET: BY TYPE (2019-2026)
  • FIGURE 48 GLOBAL SCLERODERMA THERAPEUTICS MARKET: COMPANY SHARE 2018 (%)